Glycobiology, 2001, Vol. 11, No. 3 19R-23R
© 2001 Oxford University Press
MINI REVIEW |
Glypicans in growth control and cancer
Division of Cancer Biology Research, Sunnybrook & Women’s College Health Sciences Centre, and Department of Medical Biophysics, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
Abstract
The name glypican has been assigned to a family of heparan sulfate (HS) proteoglycans that are linked to the cell membrane by a glycosyl-phosphatidylinositol anchor. To date, six family members of this family have been identified in mammals (GPC1 to GPC6) and two in Drosophila. Glypicans are expressed predominantly during development, and they are thought to play a role in morphogenesis. As HS-carrying molecules, glypicans were initially considered potential regulators of heparin-binding growth factors. This has been recently confirmed by genetic interaction experiments showing that glypicans regulate wingless signaling in Drosophila. The involvement of glypicans in the in vivo regulation of other heparin-binding growth factors, such as fibroblast growth factors, remains to be determined. Interestingly and unexpectedly, a role for GPC3 in the regulation of insulin-like growth factors has been proposed. This hypothesis is based on the phenotype of patients with Simpson-Golabi-Behmel syndrome (SGBS), an overgrowth and dysmorphic syndrome in which the GPC3 gene is mutated. Thus, it is possible that glypicans regulate different kinds of growth factors in a tissue-specific manner. In addition to its involvement in SGBS, down-regulation of GPC3 has been recently associated with the progression of several types of malignant tumors, including mesotheliomas and ovarian cancer. A role for GPC1 in pancreatic cancer progression has also been proposed.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Liu, S. Paranjpe, W. C. Bowen, A. W. Bell, J.-H. Luo, Y.-P. Yu, W. M. Mars, and G. K. Michalopoulos Investigation of the Role of Glypican 3 in Liver Regeneration and Hepatocyte Proliferation Am. J. Pathol., August 1, 2009; 175(2): 717 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Su, K. Meyer, C. D. Nandini, D. Qiao, S. Salamat, and A. Friedl Glypican-1 Is Frequently Overexpressed in Human Gliomas and Enhances FGF-2 Signaling in Glioma Cells Am. J. Pathol., June 1, 2006; 168(6): 2014 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jasuja, B. L. Allen, W. N. Pappano, A. C. Rapraeger, and D. S. Greenspan Cell-surface Heparan Sulfate Proteoglycans Potentiate Chordin Antagonism of Bone Morphogenetic Protein Signaling and Are Necessary for Cellular Uptake of Chordin J. Biol. Chem., December 3, 2004; 279(49): 51289 - 51297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Davies, F. H. Blackhall, J. H. Shanks, G. David, A. T. McGown, R. Swindell, R. J. Slade, P. Martin-Hirsch, J. T. Gallagher, and G. C. Jayson Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5178 - 5186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hippo, K. Watanabe, A. Watanabe, Y. Midorikawa, S. Yamamoto, S. Ihara, S. Tokita, H. Iwanari, Y. Ito, K. Nakano, et al. Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma Cancer Res., April 1, 2004; 64(7): 2418 - 2423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Gicquel, J Weiss, J Amiel, V Gaston, Y Le Bouc, and C D Scott Epigenetic abnormalities of the mannose-6-phosphate/IGF2 receptor gene are uncommon in human overgrowth syndromes J. Med. Genet., January 1, 2004; 41(1): e4 - 4. [Full Text] [PDF]
|
|
|
|
|
|
C. Bianco, L. Strizzi, A. Rehman, N. Normanno, C. Wechselberger, Y. Sun, N. Khan, M. Hirota, H. Adkins, K. Williams, et al. A Nodal- and ALK4-independent Signaling Pathway Activated by Cripto-1 through Glypican-1 and c-Src Cancer Res., March 15, 2003; 63(6): 1192 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. van den Born, D. S. Pikas, B. J.M. Pisa, I. Eriksson, L. Kjellen, and J. H.M. Berden Antibody-based assay for N-deacetylase activity of heparan sulfate/heparin N-deacetylase/N-sulfotransferase (NDST): novel characteristics of NDST-1 and -2 Glycobiology, January 1, 2003; 13(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cheng, K. Mani, J. van den Born, K. Ding, M. Belting, and L.-A. Fransson Nitric Oxide-dependent Processing of Heparan Sulfate in Recycling S-Nitrosylated Glypican-1 Takes Place in Caveolin-1-containing Endosomes J. Biol. Chem., November 8, 2002; 277(46): 44431 - 44439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kohl, M. Antoine, K. Reimers, and P. Kiefer FGF3 Attached to a Phosholipid Membrane Anchor Gains a High Transforming Capacity. IMPLICATIONS OF MICRODOMAINS FOR FGF3 CELL TRANSFORMATION J. Biol. Chem., August 30, 2002; 277(36): 32760 - 32767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ding, K. Mani, F. Cheng, M. Belting, and L.-A. Fransson Copper-dependent Autocleavage of Glypican-1 Heparan Sulfate by Nitric Oxide Derived from Intrinsic Nitrosothiols J. Biol. Chem., August 30, 2002; 277(36): 33353 - 33360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Schwartz and M. Domowicz Chondrodysplasias due to proteoglycan defects Glycobiology, April 1, 2002; 12(4): 57R - 68R. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shou, R. Soriano, S. W. Hayward, G. R. Cunha, P. M. Williams, and W.-Q. Gao Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression PNAS, March 5, 2002; 99(5): 2830 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Allen, M. S. Filla, and A. C. Rapraeger Role of heparan sulfate as a tissue-specific regulator of FGF-4 and FGF receptor recognition J. Cell Biol., November 26, 2001; 155(5): 845 - 858. [Abstract] [Full Text] [PDF]
|
|